Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfenex Eyes Teriparatide Launch Late Next Year As It Submits FDA Application

Executive Summary

Having moved recently its projected launch date for its follow-on teriparatide proudct, US-based Pfenex has settled on the fourth quarter of next year for potential market entry, with a commercialisation partner secured and a legal strategy at hand.

You may also be interested in...



Alvogen And Pfenex Broaden Teriparatide Collaboration

Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.

Pfenex One Step Closer To Teriparatide As FDA Accepts NDA

Pfenex maintains it can introduce a follow-on version of Eli Lilly’s Forteo in the fourth quarter of this year, after receiving a target goal date of 7 October 2019 from the FDA.

Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed

Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.

Topics

UsernamePublicRestriction

Register

GB139906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel